Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>Baseline tumor H-score levels for AXL positivity by best confirmed overall response per investigator assessment in expansion cohorts. (A) Cohort 3 (Q3W): melanoma with BRAF V600 mutation; (B) cohort 4 (Q3W): melanoma with BRAF V600 wild-type; (C) cohort 5 (Q3W): sarcoma; (D) cohort 6 (3Q4W)...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Autres auteurs: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Publié: |
2025
|
| Sujets: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Soyez le premier à ajouter un commentaire!